Skip to Content

'
Jeffrey J. Molldrem, M.D.

Present Title & Affiliation

Primary Appointment

Chief, Section of Transplantation Immunology, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor (tenured), Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Research Interests

The long-term goal of my lab is to develop immunotherapies for leukemia and other hematological diseases through an understanding of T-cell immunity against hematopoietic progenitors.  Our central hypothesis is that T-cells target and eliminate these progenitors by recognizing determinants of self-antigens when  tolerance has been reversed by aberrant self-antigen expression.  As models, we have studied myeloid leukemia and MDS and have found that CD8 lymphocytes recognized the HLA-A2-restricted PR1 peptide, derived from both P3 and NE, due to aberrant subcellular localization and over-expression.

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 900
Houston, TX 77030
Phone: (713) 563-3334
Fax: (713) 563-3364

Education & Training

Degree-Granting Education

1990 University of Minnesota, Minneapolis-St. Paul, MN, MD, Medicine
1986 Moorhead State University, Moorhead, MN, BA, Chemistry

Postgraduate Training

7/1993-7/1997 Hematology and Medical Oncology Clinical Associate and Post-doctoral Fellow, Hematology and Oncology, National Heart, Lung and Blood Institute (NHLBI) and National Cancer Institute (NCI), Bethesda, MD
7/1993-7/1997 Bone Marrow Transplant Fellowship, BMT Unit, National Heart, Lung & Blood Institute, National Institutes of Health (NIH), Bethesda, MD, Dr. John Barrett
7/1993-7/1997 Bone Marrow Transplant Fellowship, BMT Unit, Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, Dr. Ron Guess
7/1993-7/1997 Bone Marrow Transplant Fellowship, BMT Unit, Johns Hopkins University, Baltimore, MD, Dr. Richard Jones
6/1991-6/1993 Clinical Residency, Internal Medicine, University of California, Los Angeles, CA
6/1990-5/1991 Clinical Internship, Internal Medicine, University of California, Los Angeles, CA

Board Certifications

11/1996 American Board of Internal Medicine, Diplomate in Hematology
9/1993 American Board of Internal Medicine, Diplomate in Internal Medicine

Experience/Service

Academic Appointments

Faculty (tenure track), The University of Texas, Graduate School for Biomedical Sciences, Program in Immunology, Houston, TX, 1998-present

Administrative Appointments/Responsibilities

Associate Director, Center for Cancer Immunology Research, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 10/2003-present
Associate Medical Director, Bone Marrow Transplant Lab, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1998-present

Endowed Positions

Virginia H. Cockrell Distinguished Professorship in Immunology, Department of Stem Cell Transplantation - Research, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX, 2006-present

Honors and Awards

2009 American Society of Clinical Investigators
2007 Division of Cancer Medicine Mentor Award, Fellowship Program, M. D. Anderson Cancer Center
2003 Julie and Ben Rogers Award for Excellence, The University of Texas M. D. Anderson Cancer Center
2001 Faculty Scholar Award, The University of Texas M. D. Anderson Cancer Center
1993 Solomon Scholars Resident Research Award, University of California Los Angeles
1990 Chugai-Upjohn Sponsored Award, American Society of Hematology
1990 Thomas J. Livermore Award for Outstanding Research in Hematology, University of Minnesota
1989 Minnesota Medical Foundation Research Award, University of Minnesota

Professional Memberships

American Association for Cancer Research
Member, 2002-present
American Association for the Advancement of Science
Member, 1997-present
American Society for Blood and Marrow Transplantation
Member, 1997-present
American Society of Gene & Cell Therapy
Member, Genetic Vaccines Committee, 2009-present
American Society of Hematology
Member, 1997-present
Aplastic Anemia & MDS International Foundation
Member, Medical Advisory Board, 2002-2007
Harris County Medical Society, Houston, TX
Member, 2007-present
Jose Carreras International Leukemia Foundation
Member, Scientific Advisory Board, 2005-present
Texas Medical Association, TX
Member, 2007-present
The American Association of Immunologists
Member, 2006-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T-cells that target CMV, adenovirus and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 114(19):1958-67, 8/2009. PMID: 19443656.
2. Li D, Molldrem JJ, Ma Q. LFA-1 regulates CD8+ Tcell activation via TCR-mediated and LFA-1-mediated ERK1/2 signal pathways. J Biol Chem 284(31):21001-10, 7/2009. PMID: 19483086.
3. Wang Y, Li D, Nurieva R, Yang J, Sen M, Carreno R, Lu S, McIntyre BW, Molldrem JJ, Legge GB, Ma Q. LFA-1 affinity regulation is necessary for the activation and proliferation of naive T cells. J Biol Chem 284(19):12645-53, 5/2009. PMID: 19297325.
4. Yang Y, Iwanaga K, Raso MG, Wislez M, Hanna AE, Wieder ED, Molldrem JJ, Wistuba II, Powis G, Demayo FJ, Kim CF, Kurie JM. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS ONE 3(5):e2220, 5/2008. PMCID: PMC2376060.
5. Sergeeva A, Ono Y, Rios R, Molldrem JJ. High titer autoantibodies to GM-CSF in patients with AML, CML, and MDS are associated with active disease. Leukemia 22(4):783-90, 4/2008. PMID: 18216869.
6. Lee ST, Liu S, Radvanyi L, Sukhumalchandra P, Molldrem JJ, Wieder ED, Hwu P, Liu YJ, Kwak LW, Lizee G, Neelapu SS. A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. J Immunol Methods 331(1-2):13-26, 2/2008. PMCID: PMC2265521.
7. Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I, Bryan SG, Kaur I, Martin S, Wieder ED, Worth L, Cooper LJ, Petropoulos D, Molldrem JJ, Champlin RE, Shpall EJ. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 110(13):4543-51, 12/2007. PMCID: PMC2234787.
8. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 40(2):125-36, 7/2007. PMCID: PMC17530009.
9. Yao YG, Ogasawara Y, Kajigaya S, Molldrem JJ, Falcao RP, Pintao MC, McCoy Jr JP, Rizzatti EG, Young NS. Mitochondrial DNA sequence variation in single cells from leukemia patients. Blood 109(2):756-762, 1/2007. PMCID: PMC16946307.
10. Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W. Display technologies: application for the discovery of drug and gene delivery agents. Review. Adv Drug Deliv Rev 58(15):1622-54, 12/2006. PMCID: PMC1847402.
11. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM.. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nature Medicine 12(10):1160-6, 10/2006. PMCID: PMC16998485.
12. Ozdemir E, Molldrem JJ. Hookworm infection of sigmoid colon masquerading as graft-versus-host disease in an allogeneic stem cell transplant recipient after donor lymphocyte infusion for refractory acute promyelocytic leukemia. Bone Marrow Transplant 37(8):785-6, 4/2006. PMCID: PMC16501592.
13. Parmar S, Robinson SN, Komanduri K, St John L, Decker W, Xing D, Yang H, McMannis J, Champlin R, de Lima M, Molldrem J, Rieber A, Bonyhadi M, Berenson R, Shpall EJ. Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. Cytotherapy 8(2):149-57, 1/2006. PMCID: PMC16698688.
14. Bollard CM, Gottschalk S, Huls MH, Molldrem J, Przepiorka D, Rooney CM, Heslop HE. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma 47(5):837-42, 1/2006. PMCID: PMC16753867.
15. Molldrem JJ. Vaccinating transplant recipients. Nat Med 11(11):1162-3, 11/2005. PMCID: PMC16270072.
16. Rangel R, McKeller MR, Sims-Mourtada JC, Kashi C, Cain K, Wieder ED, Molldrem JJ, Pham LV, Ford RJ, Yotnda P, Guret C, Frances V, Martinez-Valdez H. Assembly of the kappa preB receptor requires a V kappa-like protein encoded by a germline transcript. J Biol Chem 280(18):17807-14, 5/2005. PMCID: PMC15757909.
17. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 11(2):108-14, 2/2005. PMCID: PMC15682071.
18. Martins SL, St John LS, Champlin RE, Wieder ED, McMannis J, Molldrem JJ, Komanduri KV. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 104(12):3429-36, 12/2004. PMCID: PMC15284108.
19. Kondo Y, Molldrem JJ. Immune-induced cytopenia: bone marrow failure syndrome. Review. Curr Hematol Rep 3(3):178-83, 5/2004. PMCID: PMC15087065.
20. Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, McMannis J, Champlin RE, Molldrem JJ, Komanduri KV. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood 103(3):1140-6, 2/2004. PMCID: PMC12907445.
21. Battiwalla M, Melenhorst J, Saunthararajah Y, Nakamura R, Molldrem J, Young NS, Barrett AJ. HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. Br J Haematol 123(3):449-53, 11/2003. PMCID: PMC14617004.
22. Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, Bollard C, Michalek J, Ghetie V, Heslop HE, Molldrem JJ, Rooney CM, Schlinder J, Vitetta E, Brenner MK. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 102, Erratum 104(6):2292-9, 9/2003. PMCID: PMC12763937.
23. Dang NH, Aytac U, Sato K, O'Brien S, Melenhorst J, Morimoto C, Barrett AJ, Molldrem JJ. T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition. Br J Haematol 121(6):857-65, 6/2003. PMCID: PMC12786796.
24. Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, Wang C, Davis MM. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 111(5):639-47, 3/2003. PMCID: PMC151894.
25. Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J, Molldrem J, Ueno N, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Review. Oncology (Williston Park) 17(1):94-100; discussion 103-7, 1/2003. PMCID: PMC12599934.
26. Melenhorst JJ, Eniafe R, Follmann D, Molldrem J, Kirby M, El Ouriaghli F, Barrett AJ. T-cell large granular lymphocyte leukemia is characterized by massive TCRBV-restricted clonal CD8 expansion and a generalized overexpression of the effector cell marker CD57. Hematol J 4(1):18-25, 1/2003. PMCID: PMC12692516.
27. Molldrem JJ, Kant S, Jiang W, Lu S. The basis of T-cell-mediated immunity to chronic myelogenous leukemia. Review. Oncogene 21(56):8668-73, 12/2002. PMCID: PMC12476312.
28. Ozdemir E, St John LS, Gillespie G, Rowland-Jones S, Champlin RE, Molldrem JJ, Komanduri KV. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 100(10):3690-7, 11/2002. PMCID: PMC12393402.
29. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 100(10):3639-45, 11/2002. PMCID: PMC12393644.
30. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno NT, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 30(6):367-73, 9/2002. PMCID: PMC12235521.
31. Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP, Simonis T, Molldrem J, Young NS, Barrett AJ. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100(5):1570-4, 9/2002. PMCID: PMC12176872.
32. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C, Liu J, Nakamura R, Young NS, Barrett AJ. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 137(3):156-63, 8/2002. PMCID: PMC12160363.
33. Guo W, Chan AP, Liang H, Wieder ED, Molldrem JJ, Etkin LD, Nagarajan L. A human mix-like homeobox gene MIXL shows functional similarity to xenopus mix.1. Blood 100(1):89-95, 7/2002. PMID: 12070013.
34. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98(4):979-87, 8/2001. PMCID: PMC11493442.
35. Kochenderfer JN, Molldrem JJ. Leukemia vaccines. Review. Curr Oncol Rep 3(3):193-200, 5/2001. PMID: 11296128.
36. Champlin R, Khouri I, Anderlini P, Gajewski J, Kornblau S, Molldrem J, Shimoni A, Ueno N, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Review. Bone Marrow Transplant 27 Suppl 2:S13-22, 5/2001. PMCID: PMC11436116.
37. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97(3):631-7, 2/2001. PMCID: PMC11157478.
38. Saunthararajah Y, Molldrem JJ, Rivera M, Williams A, Stetler-Stevenson M, Sorbara L, Young NS, Barrett JA. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol 112(1):195-200, 1/2001. PMCID: PMC11167802.
39. Shimoni A, Korbling M, Champlin R, Molldrem J. Cryofibrinogenemia and skin necrosis in a patient with diffuse large cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 26(12):1343-5, 12/2000. PMID: 11223976.
40. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, Ueno N, Giralt S, Anderlini P. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Review. Br J Haematol 111(1):18-29, 10/2000. PMCID: PMC11091179.
41. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6(9):1018-23, 9/2000. PMCID: PMC10973322.
42. Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant 25(11):1137-40, 6/2000. PMCID: PMC10849525.
43. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Review. Semin Hematol 37(1):15-29, 2000. PMCID: PMC10676908.
44. Champlin R, Khouri I, Kornblau S, Marini F, Anderlini P, Ueno NT, Molldrem J, Giralt S. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Review. Hematol Oncol Clin North Am 13(5):1041-57, vii-viii, 10/1999. PMCID: PMC10553260.
45. Raptis A, Mavroudis D, Suffredini A, Molldrem J, Rhee FV, Childs R, Phang S, Barrett A. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients. Bone Marrow Transplant 24(8):879-83, 10/1999. PMCID: PMC10516700.
46. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 59(11):2675-81, 6/1999. PMCID: PMC10363991.
47. Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Korbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 10(5):527-32, 5/1999. PMCID: PMC10416001.
48. Champlin R, Khouri I, Kornblau S, Molldrem J, Giralt S. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Review. Curr Opin Oncol 11(2):87-95, 3/1999. PMCID: PMC10188072.
49. Hensel N, Agarwala V, Jiang YZ, Mavroudis D, Molldrem J, Barrett AJ. A technique for dual determination of cytotoxic and helper lymphocyte precursor frequency by a miniaturized dye release method. Bone Marrow Transplant 23(1):71-8, 1/1999. PMCID: PMC10037053.
50. Clave E, Molldrem J, Hensel N, Raptis A, Barrett AJ. Donor-recipient polymorphism of the proteinase 3 gene: a potential target for T-cell alloresponses to myeloid leukemia. J Immunother 22(1):1-6, 1/1999. PMCID: PMC9924693.
51. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102(5):1314-22, 9/1998. PMCID: PMC9753062.
52. Raptis A, Clave E, Mavroudis D, Molldrem J, Van Rhee F, Barrett AJ. Polymorphism in CD33 and CD34 genes: a source of minor histocompatibility antigens on haemopoietic progenitor cells? Br J Haematol 102(5):1354-8, 9/1998. PMCID: PMC9753070.
53. Mavroudis DA, Dermime S, Molldrem J, Jiang YZ, Raptis A, van Rhee F, Hensel N, Fellowes V, Eliopoulos G, Barrett AJ. Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. Br J Haematol 101(3):565-70, 6/1998. PMCID: PMC9633903.
54. Barrett AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E, Dunbar C, Cottler-Fox M, Phang S, Carter C, Okunnieff P, Young NS, Read EJ. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 21(6):543-51, 3/1998. PMCID: PMC9543057.
55. Mavroudis DA, Read EJ, Molldrem J, Raptis A, Plante M, Carter CS, Phang S, Dunbar CE, Barrett AJ. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. Bone Marrow Transplant 21(5):431-40, 3/1998. PMCID: PMC9535034.
56. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99(3):699-705, 12/1997. PMCID: PMC9401087.
57. Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, Agarwala V, Barrett AJ. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90(7):2529-34, 10/1997. PMCID: PMC9326217.
58. Dermime S, Mavroudis D, Jiang YZ, Hensel N, Molldrem J, Barrett AJ. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant 19(10):989-99, 5/1997. PMCID: PMC9169643.
59. Jiang YZ, Mavroudis DA, Dermime S, Molldrem J, Hensel NF, Barrett AJ. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease. Bone Marrow Transplant 19(9):899-903, 5/1997. PMCID: PMC9156263.
60. Molldrem J, Wilson WH. Infusional chemotherapy for non-Hodgkin's lymphoma. Review. Cancer Invest 15(5):465-74, 1/1997. PMCID: PMC9316629.
61. Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J. CD34+ cell dose predicts survival, post-transplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 88(8):3223-9, 10/1996. PMCID: PMC8874224.
62. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, Fukushima P, Barrett AJ. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88(7):2450-7, 10/1996. PMCID: PMC8839835.
63. Jiang YZ, Mavroudis D, Dermime S, Hensel N, Couriel D, Molldrem J, Barrett AJ. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol 93(3):606-12, 6/1996. PMCID: PMC8652381.
64. Jiang YZ, Couriel D, Mavroudis DA, Lewalle P, Malkovska V, Hensel NF, Dermime S, Molldrem J, Barrett AJ. Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A. Immunology 87(3):481-6, 3/1996. PMCID: PMC1384120.

Book Chapters
1. Alatrash G, Molldrem JJ. Immunotherapy of AML. In: Acute Myelogenous Leukemia: Genetics, Biology and Therapy. Cancer Treatment and Research, Vol. 145. Ed(s) Nagarajan L. Springer: New York, 2008. PMID: 9780387692579.
2. Riddell S, Molldrem JJ. Understanding and enhancing the graft-versus-leukemia effect after hematopoietic stem cell transplantation. In: Hematopoietic Stem Cell Transplantation. Cancer Treatment and Research, Vol. 144. Ed(s) Bishop MR. Springer: New York, 2008. PMID: 9780387785790.
3. Kurbegov D Molldrem J. Peptide Vaccination of Myeloid Leukemia. In: Regenerative and Cell Therapy, Clinical Advances. Supplement 11. Ernst Schering Research Foundation Workshop, 131-144, 2005.
4. Lu S, Wieder E, Komanduri K, Ma Q, Molldrem JJ. Vaccines in Leukemia. In: Adv Pharmacol. 51. Elsevier, Inc, 255-70, 2004. PMID: 15464913.
5. Molldrem JJ Shlomchik W. Graft-vs-Leukemia Effects. In: Graft vs. Host Disease. Marcel Dekker, Inc, 155-193, 2003.
6. Molldrem JJ. T Cell Large Granular Lymphocyte Lymphoproliferative Disorder. In: Bone Marrow Failure Syndromes. Saunders, 207-215, 2000.
7. Molldrem JJ. Tissue Antigens as Targets for GVL. In: Allogeneic Immunotherapy. Marcel Dekker, Inc, 135-155, 2000.
8. Roth J, Molldrem J, Smythe W. The Current Status of Cancer Gene Therapy Trials. In: Cancer: Principles and Practice of Oncology Updates. Volume 13 No. 11. Lippincott-Raven, 1-15, 1999.

Grant & Contract Support

Title: Therapy of CML, Tissue Procurement and Cell Bank (PC-E)
Funding Source: NIH/NCI
Role: Core Leader
Principal Investigator: Champlin
Duration: 12/1/2008 - 11/30/2013
 
Title: Translational Development of Novel Vaccine Therapies
Funding Source: Leukemia and Lymphoma Society
Role: Project Leader
Principal Investigator: Kwak
Duration: 10/1/2007 - 9/30/2012
 
Title: Targeted Immune Therapy with Donor Derived Tumor Idiotype Specific T-Cells
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 10/1/2006 - 9/30/2009
 
Title: Cyclin E-Derived Peptides as Targets of T Lymphocyte-Mediated Immunity Against Leukemia
Funding Source: Gillson-Longenbaugh Foundation
Role: Principal Investigator
Duration: 9/1/2006 - present
 
Title: Cyclin E-Derived Peptides as Targets of T Lymphocyte-Mediated Immunity Against Leukemia
Funding Source: Carl C. Anderson Sr. and Marie Jo Anderson Charitable Foundation
Role: Principal Investigator
Duration: 9/1/2006 - present
 
Title: New Approaches to the Biology and Treatment of MDS (PP-5)
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: Kantarjian
Duration: 6/21/2005 - 5/31/2010
 
Title: Antigen-Specific Immunotherapy of Leukemia, (PP-2)
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: Issa
Duration: 8/5/2003 - 4/30/2013
 
Title: Therapy of CML, CML Immunity (PP-3), no-cost extension
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: Champlin
Duration: 2/12/1997 - 2/28/2010
 
Title: Therapy of CML, Tissue Procurement and Cell Bank (PC-E), no-cost extension
Funding Source: NIH/NCI
Role: Core Leader
Principal Investigator: Champlin
Duration: 2/12/1997 - 2/28/2010

Last updated: 11/13/2009